D-Index & Metrics Best Publications
Research.com 2022 Best Scientist Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 179 Citations 158,946 1,290 World Ranking 131 National Ranking 18
Best Scientists D-index 179 Citations 160,845 1,660 World Ranking 439 National Ranking 47

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Scientist Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Surgery

His scientific interests lie mostly in Rheumatoid arthritis, Internal medicine, Surgery, Arthritis and Rheumatology. His Rheumatoid arthritis research integrates issues from Connective tissue disease, Physical therapy, Methotrexate and Rituximab. His biological study spans a wide range of topics, including Gastroenterology and Placebo.

As a member of one scientific family, he mostly works in the field of Gastroenterology, focusing on Infliximab and, on occasion, Etanercept. His work investigates the relationship between Arthritis and topics such as Pathology that intersect with problems in Synovial membrane. His Rheumatology study combines topics in areas such as Rheumatoid factor, Visual analogue scale, Rheumatism, Pharmacotherapy and Abatacept.

His most cited work include:

  • 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. (4441 citations)
  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (3425 citations)
  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (2688 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Rheumatoid arthritis, Immunology, Arthritis and Rheumatology. His research integrates issues of Gastroenterology, Placebo and Surgery in his study of Internal medicine. He combines subjects such as Severity of illness, Adverse effect and Infliximab with his study of Surgery.

His study in the field of Synovitis is also linked to topics like In patient. His research on Arthritis often connects related areas such as Pathology. His Rheumatology research incorporates themes from Rheumatism and Cohort.

He most often published in these fields:

  • Internal medicine (66.85%)
  • Rheumatoid arthritis (60.74%)
  • Immunology (24.62%)

What were the highlights of his more recent work (between 2017-2021)?

  • Internal medicine (66.85%)
  • Rheumatoid arthritis (60.74%)
  • Arthritis (22.27%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Rheumatoid arthritis, Arthritis, Clinical trial and Synovitis. His research on Internal medicine often connects related topics like Gastroenterology. His study in Rheumatoid arthritis is interdisciplinary in nature, drawing from both Methotrexate, Discontinuation and Oncology.

He has included themes like Placebo and Early rheumatoid arthritis in his Methotrexate study. The various areas that he examines in his Arthritis study include Randomized controlled trial and Autoimmunity, Disease. Paul Emery focuses mostly in the field of Synovitis, narrowing it down to matters related to Inflammatory arthritis and, in some cases, Odds ratio.

Between 2017 and 2021, his most popular works were:

  • Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia (292 citations)
  • Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia (292 citations)
  • Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (260 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Disease
  • Cancer

His scientific interests lie mostly in Internal medicine, Rheumatoid arthritis, Arthritis, Clinical trial and Rheumatology. His research in Internal medicine intersects with topics in Gastroenterology and Placebo. His Rheumatoid arthritis research incorporates elements of Discontinuation, Cohort and Rituximab.

His Arthritis research includes themes of Magnetic resonance imaging, Lupus erythematosus and Autoimmunity. His work carried out in the field of Clinical trial brings together such families of science as Psoriatic arthritis, Systematic review, Adverse effect, Evidence-based medicine and Methylprednisolone acetate. His Rheumatology research includes elements of Rheumatism, Severity of illness and Abatacept.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Daniel Aletaha;Tuhina Neogi;Alan J. Silman;Julia Funovits.
Arthritis & Rheumatism (2010)

10141 Citations

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

P E Lipsky;D M van der Heijde;E W St Clair;D E Furst.
The New England Journal of Medicine (2000)

4752 Citations

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

R Maini;E W St Clair;F Breedveld;D Furst.
The Lancet (1999)

3606 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch.
Annals of the Rheumatic Diseases (2014)

3425 Citations

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Jonathan C W Edwards;Leszek Szczepanski;Jacek Szechinski;Anna Filipowicz-Sosnowska.
The New England Journal of Medicine (2004)

3157 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

J. S. Smolen;R. Landewé;F. C. Breedveld;M. Dougados.
Revmatologiia (2011)

3007 Citations

Treating rheumatoid arthritis to target: recommendations of an international task force

Josef S. Smolen;Daniel Aletaha;Johannes W J W Bijlsma;Ferdinand C Breedveld.
Annals of the Rheumatic Diseases (2010)

2471 Citations

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy : Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Stanley B Cohen;Paul Emery;Maria W Greenwald;Maxime Dougados.
Arthritis & Rheumatism (2006)

2212 Citations

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados.
Annals of the Rheumatic Diseases (2010)

2195 Citations

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang.
Arthritis & Rheumatism (2011)

1541 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Paul Emery

Maxime Dougados

Maxime Dougados

Hôpital Cochin

Publications: 318

Désirée van der Heijde

Désirée van der Heijde

Leiden University Medical Center

Publications: 305

Mikkel Østergaard

Mikkel Østergaard

University of Copenhagen

Publications: 269

Paul P. Tak

Paul P. Tak

GlaxoSmithKline (United Kingdom)

Publications: 268

Josef S. Smolen

Josef S. Smolen

Medical University of Vienna

Publications: 268

Yoshiya Tanaka

Yoshiya Tanaka

University of Occupational and Environmental Health Japan

Publications: 245

Robert Landewé

Robert Landewé

University of Amsterdam

Publications: 234

Tsutomu Takeuchi

Tsutomu Takeuchi

Keio University

Publications: 229

Philip J. Mease

Philip J. Mease

University of Washington

Publications: 221

Dennis McGonagle

Dennis McGonagle

University of Leeds

Publications: 216

Laure Gossec

Laure Gossec

Sorbonne University

Publications: 207

Tore K. Kvien

Tore K. Kvien

University of Oslo

Publications: 204

Xavier Mariette

Xavier Mariette

University of Paris-Sud

Publications: 204

Georg Schett

Georg Schett

University of Erlangen-Nuremberg

Publications: 202

Bernard Combe

Bernard Combe

University of Montpellier

Publications: 199

Tom W. J. Huizinga

Tom W. J. Huizinga

Leiden University Medical Center

Publications: 196

Something went wrong. Please try again later.